Safety and efficacy of eletriptan in the treatment of acute migraine

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 115-128

  Takiya, Liza ^a   Piccininni, Lisa C ^b   Kamath, Veena ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b New Jersey Health Care System   (United States)

^c UNION MEMORIAL HOSPITAL   (United States)

Author keywords

5 HT agonist; Eletriptan; Migraine headache; Serotonin agonist; Triptan

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; CAFFEINE; CYTOCHROME P450 3A4; ELETRIPTAN; ERGOTAMINE TARTRATE; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SPASM; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; HALF LIFE TIME; HEADACHE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; LIPOPHILICITY; META ANALYSIS; MIGRAINE; MYASTHENIA; NAUSEA; PARESTHESIA; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; THORAX DISEASE; THORAX PAIN; VOMITING; XEROSTOMIA;

ACUTE DISEASE; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; MIGRAINE DISORDERS; PYRROLIDINES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 30544448988     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.115     Document Type: Review

References (46)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9.
2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the US: disability and economic costs. Arch Intern Med 1999;159:813-18.
3. Ferrari MD. Migraine. Lancet 1998;351(9108):1043-51.
4. Napier C, Stewart M, Heather M, Hopkins B, McHarg A, Wallis R. Characterisation of the 5HT receptor binding profile of eletriptan and kinetics of eletriptan binding at human 5-HT 1B and 5-HT 1D receptors. Eur J Pharmacol 1999;368:259-68.
5. Johnson DE, Rollema H, Schmidt AW, McHarg AD. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan, and sumatriptan in rat brain. Eur J Pharmacol 2001;425:203-10.
6. VanDenBrink AM, van den Broek RW, de Vries R, Bogers AJJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000;55(10):1524-30.
7. van den Broek RW, VanDenBrink AM, de Vries R, et al. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol 2000;407:165-73.
8. Gupta P, Butler P, Shepperson NB, McHarg A. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT 1b/1d receptor agonist. Eur J Pharmacol 2000;398(1):73-81.
9. Milton KA, Scott NR, Allen MJ, et al. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT 1B/1D agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002;42:528-39.
10. Muir DF, McCann GP, Swan L, Clark AL, Hillis WS. Hemodynamic and coronary effects of intravenous eletriptan, a 5HT 1B/1D receptor agonist. Clin Pharmacol Ther 1999;66(1):85-90.
11. Goldstein J, Massey K, Kirby S, et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 2004;24:515-21.
12. Drug Facts and Comparisons. 5-HT1 serotonin agonists. Available from www.efactsonline.com/Fac/servlet/Mono Viewer?sys=1&id=1065&sec= 3&set=jjfal. Accessed February 2005.
13. Ngo J, Rabasseda X, Castaner J. Eletriptan. Drugs Future 1997;22(3):221-4.
14. Shah AK, Harris SC, Greenhalgh C, Morganroth J. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 2002;42:520-7.
15. Deleu D, Hanssens Y. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Acta Neurol Belg 1999;99(2):85-95.
16. Hyland R, Jones BC, McCleverty P, et al. In vitro metabolism of eletriptan in human liver microsomes [abstr]. Cephalalgia 1998;18:404.
17. Pichard-Garcia L, Hyland R, Baulieu J, Fabre JM, Milton A, Maurel P. Human hepatocytes in primary culture predict lack of cytochrome p450 3A4 induction by eletriptan in vivo. Drug Metab Dispos 2000;28(1):51-7.
18. Tepper SJ. Safety and rational use of the triptans. Med Clin North Am 2001;85(4):959-70.
19. Diener HC, Kaube H, Limmorth V. Antimigraine drugs. J Neurol 1999;246(7):515-19.
20. Bardsley-Elliot A, Noble S. Eletriptan: new drug profile. CNS Drugs 1999;12(4):325-33.
21. Loh SC, Wong KS. Eletriptan. Med Prog 2002:40-6.
22. Shah AK, LaBoy-Goral L, Scott N, Morese T, Apseloff G. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in health volunteers. J Clin Pharmacol 2001;41:1339-44.
23. Pfizer, Inc. Relpax (eletriptan hydrobromine) tablets prescribing information. Available from www.relpax.com/pdf/pi_final.pdf. Accessed February 2005.
24. 1B/1D receptor agonist for the acute treatment of migraine. Formulary 2000;35:129-41.
25. Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003;43:202-13.
26. Stark R, Dahlof C, Haughie S, Hettiarachchi J. Efficacy, safety, and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002;22:23-32.
27. Farkkila M, Diesen J, Dahlof C, Stovner L, ter Bruggen J. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463-71.
28. Goadsby PJ, Ferrari MD, Diesen J, Stovner LJ, Senard JM. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000;54:156-63.
29. Sandrini G, Farkkila M, Burgess G, Forster E, Haughie S. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002;59:1210-17.
30. Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003;43:214-22.
31. Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirhead N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003;23:942-52.
32. Garcia-Ramos G, MacGregor EA, Billiard B, Bordini CA, Leston J, Hettiarachchi J. Comparative efficacy of eletriptan versus naratriptan in the acute treatment of migraine. Cephalalgia 2003;23:869-76.
33. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicentre, randomized, double-blind, placebo-controlled comparison. Eur Neurol 2002;47:99-107.
34. Farkkila M. A dose-finding study of eletriptan (UK-116,044) (5-30 mg) for the acute treatment of migraine [abstr]. Cephalalgia 1996;16:387.
35. Oldman AD, Smith LA, McQuay HJ, Moore A. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97:247-57.
36. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58.
37. Belsey JD. Cost effectiveness of oral triptan therapy: a transnational comparison based on a meta-analysis of randomized clinical trials. Curr Med Res Opin 2004;20(5):659-69.
38. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42(suppl 2):S84-92.
39. Hettiarachchi J. Adverse event profile of oral eletriptan: review of clinical trial experience [abstr]. Cephalalgia 1999;19:355.
40. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology 2000;55:754-63.
41. Weitzel KW, Thomas ML, Small RE, Goode J-V. Migraine: a comprehensive review of new treatment options. Pharmacotherapy 1999;19(8):957-73.
42. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998;56(5):811-24.
43. Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol 2001;58:1479-80.
44. Dasbach EJ, Carides GW, Gerth WC, et al. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 2000;20(9):830-4.
45. Wells N, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2000;18(6):557-66.
46. Wells N, Hettiarachchi J, Drummond M, Carter D, Parpia T, Pang F. A Cost-effective analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health 2003;6(4):438-47.